Contact Us

Thank you for your interest in EVZIO. We look forward to hearing from you and will help answer any questions you may have.

General Product Information: 1-855-77-EVZIO (1-855-773-8946)

Contact customer service for general information about EVZIO.

  • Live customer support is available. Call 1-855-77-EVZIO (1-855-773-8946) Monday through Saturday, 8 AM to 8 PM ET.

EVZIO2YOU: 1-855-77-EVZIO (1-855-773-8946)

EVZIO2YOU is the direct-delivery service that helps patients and their care partners fill their EVZIO prescription.

  • For questions about EVZIO2YOU, call 1-855-77-EVZIO (1-855-773-8946) Monday through Saturday, 8 AM to 8 PM ET.

KALÉO CARES Patient Assistance Program: 1-844-MYEVZIO (1-844-693-8946)

The KALÉO CARES Patient Assistance Program helps provide EVZIO at no cost to patients who qualify.

  • If the physician’s office calls to check on the patient’s eligibility or for any other questions, please note that return calls will come from area code 502. To return the call, contact 1-844-MYEVZIO (1-844-693-8946).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATION

EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.

Seek emergency medical assistance immediately after use. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.

The following warnings and precautions should be taken when administering EVZIO:

The following adverse reactions were most commonly observed in EVZIO clinical studies: dizziness and injection site erythema.

Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated signs and symptoms of opioid withdrawal including: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In the neonate, opioid withdrawal signs and symptoms also included: convulsions, excessive crying, and hyperactive reflexes.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click for full Prescribing Information and Patient Information.

Indication

EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.

Important Safety Information

EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.

INDICATION

EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.

Important Safety Information

EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.

INDICATION

EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.